아시아 태평양 간질 시장 전망 2030 - 지역 분석 - 유형별(진행성 근간대성 간질, 반사성 간질, 전신성 간질 및 기타), 투여 경로(경구, 비경구 및 기타), 치료 유형(1세대 약물, 2세대 약물 및 3세대 약물), 연령대(성인 및 어린이), 유통 채널(병원 약국, 소매 약국 및 기타)
기관에서 실시하는 인식 제고 프로그램 급증으로 아시아 태평양 간질 시장이 활성화됨
간질, 간질 증상 및 조기 진단의 중요성에 대한 인식이 높아짐에 따라 의료 지원을 찾는 환자가 급증했습니다. Epilepsy Foundation, Epilepsy Society, American Epilepsy Society, Epilepsy Association of Central Florida와 같은 기관은 사람들에게 이 질병에 대한 교육을 제공하는 데 중요한 역할을 합니다. 이러한 기관의 참여로 진단율이 증가하고 간질 치료가 필요한 환자 집단이 확대되었습니다. 전 세계적으로 기관에서 수많은 인식 제고 캠페인을 실시하여 이 질환과 이용 가능한 치료법에 대한 인식을 확산하고 있습니다. 2023년, 간질의 보라색 날에 하이데라바드(인도)의 Aster Prime Hospitals는 Krishna Kant Park의 Walkers Association과 협력하여 인식 제고 활동을 개최했습니다. 워커와 요가 수행자를 포함한 총 150명의 참가자가 이 세션에 참석했습니다. 또한, 간질을 앓고 있는 호주인의 삶의 질을 개선하기 위해 Epilepsy Action Australia는 인식 제고, 교육 및 개인에게 필요한 기술 제공을 목표로 하는 다양한 도구와 서비스를 제공합니다. 따라서 이러한 이니셔티브와 인식 제고 캠페인은 간질 진단 및 치료 증가로 이어져 시장에 수익성 있는 성장 기회를 제공합니다.
아시아 태평양 간질 시장 개요
아시아 태평양 간질 시장은 중국, 일본, 인도, 호주, 한국 및 기타 아시아 태평양 지역을 기준으로 분석됩니다. 세계보건기구(WHO) 보고서에 따르면 간질은 선진국보다 개발도상국에서 더 흔하며 각각 6.1%와 5.0%의 유병률을 차지합니다.
아시아 태평양 간질 시장 수익 및 2030년까지의 예측(백만 달러)
아시아 태평양 간질 시장 세분화
아시아 태평양 간질 시장은 유형, 투여 경로, 치료 유형, 연령대, 유통 채널 및 국가로 분류됩니다.
유형에 따라 아시아 태평양 간질 시장은 진행성 근간대성 간질, 반사성 간질, 전신성 간질 및 기타로 분류됩니다. 전신성 간질 부문은 2022년에 가장 큰 시장 점유율을 차지했습니다.
투여 경로 측면에서 아시아 태평양 간질 시장은 경구, 비경구 및 기타로 분류됩니다. 경구 부문은 2022년에 가장 큰 시장 점유율을 차지했습니다.
치료 유형별로 아시아 태평양 간질 시장은 1세대 약물, 2세대 약물, 3세대 약물로 세분화됩니다. 3세대 약물 부문은 2022년에 가장 큰 시장 점유율을 차지했습니다.
연령대를 기준으로 아시아 태평양 간질 시장은 성인과 어린이로 나뉩니다. 성인 부문은 2022년에 더 큰 시장 점유율을 차지했습니다.
유통 채널 측면에서 아시아 태평양 간질 시장은 병원 약국, 소매 약국 및 기타로 분류됩니다. 병원 약국 부문은 2022년에 가장 큰 시장 점유율을 차지했습니다.
국가별로 아시아 태평양 간질 시장은 중국, 일본, 인도, 호주, 한국 및 기타 아시아 태평양 지역으로 세분화됩니다. 중국은 2022년 아시아 태평양 간질 시장 점유율에서 우위를 차지했습니다.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, H. Lundbeck AS는 아시아 태평양 간질 시장에서 활동하는 주요 기업 중 일부입니다.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Asia Pacific Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - Asia Pacific Analysis
6.1 Asia Pacific: Epilepsy Market
7. Asia Pacific Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. Asia Pacific Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. Asia Pacific Epilepsy Market - Country Analysis
12.1 Asia Pacific Epilepsy Market Overview
12.1.1 Asia Pacific: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 China: Epilepsy Market Overview
12.1.1.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 China: Epilepsy Market Breakdown, by Type
12.1.1.2.2 China: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 China: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 China: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 Japan: Epilepsy Market Overview
12.1.1.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 Japan: Epilepsy Market Breakdown, by Type
12.1.1.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 Japan: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 India: Epilepsy Market Overview
12.1.1.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 India: Epilepsy Market Breakdown, by Type
12.1.1.6.2 India: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 India: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 India: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Australia: Epilepsy Market Overview
12.1.1.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Australia: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Australia: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.9 South Korea: Epilepsy Market Overview
12.1.1.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.10.1 South Korea: Epilepsy Market Breakdown, by Type
12.1.1.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
12.1.1.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
12.1.1.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
12.1.1.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.11 Rest of Asia Pacific: Epilepsy Market Overview
12.1.1.12 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.12.1 Rest of Asia Pacific: Epilepsy Market Breakdown, by Type
12.1.1.12.2 Rest of Asia Pacific: Epilepsy Market Breakdown, by Route of Administration
12.1.1.12.3 Rest of Asia Pacific: Epilepsy Market Breakdown, by Treatment Type
12.1.1.12.4 Rest of Asia Pacific: Epilepsy Market Breakdown, by Age Group
12.1.1.12.5 Rest of Asia Pacific: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 LivaNova Plc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Medtronic Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 GSK Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 H. Lundbeck AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Insight Partners
?
List of Tables
Table 1. Asia Pacific Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
Table 11. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 27. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 28. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 29. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 32. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 33. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 34. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 35. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 36. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 37. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 38. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 39. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 40. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 41. Recent Organic Growth Strategies in Epilepsy Market
Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. Asia Pacific Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Asia Pacific: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Asia Pacific: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in Epilepsy Market
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.